Nutra Pharma Corp
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases in the United States. The company offers Nyloxin, an over-the-counter (OTC) pain reliever; Nyloxin Extra Strength, a non-narcotic and non-addictive treatment fo… Read more
Nutra Pharma Corp (NPHC) - Total Assets
Latest total assets as of September 2024: $558.84K USD
Based on the latest financial reports, Nutra Pharma Corp (NPHC) holds total assets worth $558.84K USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nutra Pharma Corp - Total Assets Trend (2001–2025)
This chart illustrates how Nutra Pharma Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nutra Pharma Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Nutra Pharma Corp's total assets of $558.84K consist of 44.2% current assets and 55.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $21.66K | 2.9% |
| Inventory | $23.87K | 3.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Nutra Pharma Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nutra Pharma Corp's current assets represent 44.2% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, the same as 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 100.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 3.2% of total assets.
Nutra Pharma Corp Competitors by Total Assets
Key competitors of Nutra Pharma Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Nutra Pharma Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Nutra Pharma Corp generates 0.58x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Nutra Pharma Corp generates $ 1083.15 in net profit.
Nutra Pharma Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 0.02 |
| Quick Ratio | 0.02 | 0.03 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.90 Million | $ -15.70 Million | $ -7.73 Million |
Nutra Pharma Corp - Advanced Valuation Insights
This section examines the relationship between Nutra Pharma Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 17.9% |
| Total Assets | $754.91K |
| Market Capitalization | $1.41 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nutra Pharma Corp's assets above their book value (1.86 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Nutra Pharma Corp's assets grew by 17.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nutra Pharma Corp (2001–2025)
The table below shows the annual total assets of Nutra Pharma Corp from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $754.91K | +17.88% |
| 2023-12-31 | $640.40K | -15.17% |
| 2022-12-31 | $754.91K | -3.22% |
| 2021-12-31 | $780.02K | +451.58% |
| 2020-12-31 | $141.42K | -58.39% |
| 2019-12-31 | $339.83K | +140.30% |
| 2018-12-31 | $141.42K | -63.70% |
| 2017-12-31 | $389.57K | +81.82% |
| 2016-12-31 | $214.26K | -44.73% |
| 2015-12-31 | $387.64K | +0.10% |
| 2014-12-31 | $387.26K | +199.36% |
| 2013-12-31 | $129.36K | -57.29% |
| 2012-12-31 | $302.88K | +32.26% |
| 2011-12-31 | $229.00K | -69.61% |
| 2010-12-31 | $753.43K | -39.86% |
| 2009-12-31 | $1.25 Million | +1068.33% |
| 2008-12-31 | $107.22K | -25.64% |
| 2007-12-31 | $144.19K | +36.33% |
| 2006-12-31 | $105.76K | -21.63% |
| 2005-12-31 | $134.94K | -77.28% |
| 2004-12-31 | $593.82K | -86.62% |
| 2003-12-31 | $4.44 Million | +441.86% |
| 2002-12-31 | $819.33K | -49.84% |
| 2001-12-31 | $1.63 Million | -- |